Sequent Scientific Valuation

Is SEQUENT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SEQUENT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SEQUENT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SEQUENT's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SEQUENT?

Key metric: As SEQUENT is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SEQUENT. This is calculated by dividing SEQUENT's market cap by their current revenue.
What is SEQUENT's PS Ratio?
PS Ratio	3.4x
Sales	₹14.49b
Market Cap	₹49.45b

SEQUENT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	3.7x
Enterprise Value/EBITDA	37.7x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does SEQUENT's PS Ratio compare to its peers?

The above table shows the PS ratio for SEQUENT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	5x
JSLL Jeena Sikho Lifecare	12.7x	n/a	₹47.1b
524735 Hikal	2.6x	13.2%	₹47.6b
AARTIPHARM Aarti Pharmalabs	2.9x	n/a	₹56.9b
524348 Aarti Drugs	1.8x	13.4%	₹42.0b
SEQUENT Sequent Scientific	3.4x	n/a	₹49.4b

Price-To-Sales vs Peers: SEQUENT is good value based on its Price-To-Sales Ratio (3.4x) compared to the peer average (5x).

Price to Sales Ratio vs Industry

How does SEQUENT's PS Ratio compare vs other companies in the IN Pharmaceuticals Industry?

13 Companies	Price / Sales	Estimated Growth	Market Cap
NECLIFE Nectar Lifesciences	0.4x	n/a	US$87.60m
539561 Remedium Lifecare	0.07x	n/a	US$26.82m
532637 Mangalam Drugs & Organics	0.5x	n/a	US$20.01m
524412 Aarey Drugs & Pharmaceuticals	0.3x	n/a	US$19.20m

13 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: SEQUENT is expensive based on its Price-To-Sales Ratio (3.4x) compared to the Indian Pharmaceuticals industry average (3.1x).

Price to Sales Ratio vs Fair Ratio

What is SEQUENT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SEQUENT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	3.4x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate SEQUENT's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Vivimed Labs

₹410.4m

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India.

VIVIMEDLAB

₹4.95

-45.9%

Sanofi India

₹142.5b

Manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally.

SANOFI

₹6,197.45

0.8%

-23.0%

Novartis India

₹26.1b

Operates as a healthcare company in India.

500672

₹1,058.30

3.5%

52.4%